STANDARD BIOTOOLS INC.(LAB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,997 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
LAB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for STANDARD BIOTOOLS INC. (LAB), a Technology sector company. 13F Pro's AI-powered ranking engine scores LAB at 38.8/100 on a 32-signal composite quality model, placing it at rank #1,997 of 2,879 stocks — the bottom half of the AI-ranked universe. LAB scores in the top quartile across profitability (94.3). Areas of concern include free cash flow (5.5) and revenue growth (13.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), STANDARD BIOTOOLS INC. reports quarterly revenue of $21.1M, net income of $127.1M, free cash flow of $-47.2M. Top institutional holders of LAB by reported 13-F value include Casdin Capital,, VIKING GLOBAL INVESTORS, MAK CAPITAL ONE, based on the most recent SEC filings. LAB trades on the Nasdaq exchange and files with the SEC under CIK 1162194. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STANDARD BIOTOOLS INC. directly from SEC EDGAR. STANDARD BIOTOOLS INC.'s 13F Pro composite quality score has ranged between 8 and 40 since 2022, currently 38.8 — an improving long-term trajectory across 51 quarterly and live scoring snapshots.
Revenue
Q1 2026
$21.1M
Net Income
Q1 2026
$127.1M
Free Cash Flow
Q1 2026
$-47.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-6.2% YoYNet Income
+46.1% YoYOperating Income
+13.5% YoYEPS (Diluted)
+61.5% YoYTotal Assets
-7.3% YoYTotal Debt
Op. Cash Flow
+48.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $85.3M -6.2% | $91.0M -14.4% | $106.3M +8.6% | $97.9M -29.1% | $138.1M +22.3% | $113.0M |
| Net Income | $-74.9M +46.1% | $-138.9M -86.0% | $-74.7M +60.7% | $-190.1M -258.5% | $-53.0M +10.2% | $-59.0M |
| Operating Income | $-110.2M +13.5% | $-127.5M -66.4% | $-76.6M +34.1% | $-116.2M -127.7% | $-51.0M -6.0% | $-48.2M |
| EPS (Diluted) | $-0.20 +61.5% | $-0.52 +44.7% | $-0.94 +61.3% | $-2.43 -228.4% | $-0.74 | — |
| Total Assets | $567.8M -7.3% | $612.3M +89.5% | $323.1M -17.2% | $390.3M +20.2% | $324.8M +7.0% | $303.6M |
| Total Debt | — | $299.0K -99.5% | $63.5M -2.1% | $64.9M | — | — |
| Operating Cash Flow | $-74.3M +48.2% | $-143.5M -231.4% | $-43.3M +51.6% | $-89.4M -479.7% | $-15.4M +38.8% | $-25.2M |
Get alerted when LAB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for STANDARD BIOTOOLS INC. including:
Top Institutional Holders of LAB
Casdin Capital, LLC
$81.6M88,783,856 shVIKING GLOBAL INVESTORS LP
$53.9M58,651,170 shMAK CAPITAL ONE LLC
$24.1M26,172,626 shBlackRock, Inc.
$22.8M24,756,084 shLong Focus Capital Management, LLC
$14.7M16,015,721 shVANGUARD CAPITAL MANAGEMENT LLC
$11.8M12,816,070 shGEODE CAPITAL MANAGEMENT, LLC
$6.7M7,289,336 shSTATE STREET CORP
$6.0M6,556,509 shHollow Brook Wealth Management LLC
$5.2M5,653,381 shNeuberger Berman Group LLC
$4.3M4,657,585 sh
| Fund | Value | Shares |
|---|---|---|
| Casdin Capital, LLC | $81.6M | 88,783,856 |
| VIKING GLOBAL INVESTORS LP | $53.9M | 58,651,170 |
| MAK CAPITAL ONE LLC | $24.1M | 26,172,626 |
| BlackRock, Inc. | $22.8M | 24,756,084 |
| Long Focus Capital Management, LLC | $14.7M | 16,015,721 |
| VANGUARD CAPITAL MANAGEMENT LLC | $11.8M | 12,816,070 |
| GEODE CAPITAL MANAGEMENT, LLC | $6.7M | 7,289,336 |
| STATE STREET CORP | $6.0M | 6,556,509 |
| Hollow Brook Wealth Management LLC | $5.2M | 5,653,381 |
| Neuberger Berman Group LLC | $4.3M | 4,657,585 |
More Technology Companies
View all Technology →Put LAB on your watchlist
Track score changes the day STANDARD BIOTOOLS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LAB a good stock to buy?
13F Pro's AI-powered analysis of STANDARD BIOTOOLS INC. (LAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LAB are available on the LAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own LAB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of STANDARD BIOTOOLS INC.'s investment landscape.